[go: up one dir, main page]

UA90659C2 - Аналоги хиназолина как ингибиторы рецепторных тирозинкиназ - Google Patents

Аналоги хиназолина как ингибиторы рецепторных тирозинкиназ

Info

Publication number
UA90659C2
UA90659C2 UAA200602710A UAA200602710A UA90659C2 UA 90659 C2 UA90659 C2 UA 90659C2 UA A200602710 A UAA200602710 A UA A200602710A UA A200602710 A UAA200602710 A UA A200602710A UA 90659 C2 UA90659 C2 UA 90659C2
Authority
UA
Ukraine
Prior art keywords
tyrosine kinase
kinase inhibitors
receptor tyrosine
quinazoline analogs
analogs
Prior art date
Application number
UAA200602710A
Other languages
English (en)
Ukrainian (uk)
Inventor
Эли Уоллейс
Георгий Топалов
Джозеф ЛИССИКАТОС
Александр Бакмельтер
Цян Чжао
Original Assignee
Аррей Байофарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аррей Байофарма Инк. filed Critical Аррей Байофарма Инк.
Publication of UA90659C2 publication Critical patent/UA90659C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Данное изобретение касается аналогов хиназолина Формулы И:,где А прикреплено к по меньшей мере одному из углеродов в положении 5, 6, 7 или 8 бициклического кольца, и кольцо замещено как минимум двумя независимыми группами R.Изобретение также включает способы применения соединений Формулы И как ингибиторов рецепторной тирозинкиназы типа И и для лечения гиперпролиферативных заболеваний, таких как рак.
UAA200602710A 2003-08-14 2004-08-10 Аналоги хиназолина как ингибиторы рецепторных тирозинкиназ UA90659C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/642,440 US7501427B2 (en) 2003-08-14 2003-08-14 Quinazoline analogs as receptor tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
UA90659C2 true UA90659C2 (ru) 2010-05-25

Family

ID=34549763

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200602710A UA90659C2 (ru) 2003-08-14 2004-08-10 Аналоги хиназолина как ингибиторы рецепторных тирозинкиназ

Country Status (6)

Country Link
US (7) US7501427B2 (ru)
EP (1) EP2377539A1 (ru)
CN (1) CN1852714A (ru)
SI (1) SI1660090T1 (ru)
UA (1) UA90659C2 (ru)
ZA (1) ZA200601333B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1660090B1 (en) * 2003-08-14 2012-11-21 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US20050287593A1 (en) * 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
BRPI0510617A (pt) * 2004-05-03 2007-10-30 Schering Corp uso de expressão de il-17 para prever inflamação de pele; processos de tratamento
PL2090575T3 (pl) 2005-11-15 2011-09-30 Array Biopharma Inc Sposoby i związki pośrednie do otrzymywania pochodnych N4-fenylo-chinazolino-4-aminy
AU2008236995A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Dosages and methods for the treatment of cancer
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
HRP20171537T1 (hr) 2009-11-05 2017-12-15 Rhizen Pharmaceuticals S.A. Novi modulatori benzopiran kinaze
KR101992311B1 (ko) 2011-05-04 2019-09-27 리젠 파마슈티컬스 소시에떼 아노님 단백질 키나아제의 조절제로서 신규한 화합물
UA116875C2 (uk) 2011-10-14 2018-05-25 Еррей Біофарма Інк. Поліморфи arry-380 селективного інгібітору erbb2 і фармацевтичні композиції, що їх містять
AU2012322039C1 (en) 2011-10-14 2021-04-29 Array Biopharma Inc. Solid dispersions of a Erb2 (HER2) inhibitor
LT2870157T (lt) 2012-07-04 2017-12-11 Rhizen Pharmaceuticals S.A. Selektyvieji pi3k delta inhibitoriai

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2583774A (en) * 1948-04-30 1952-01-29 Merck & Co Inc Vitamin b6 derivatives
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
CA1340821C (en) * 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5204348A (en) 1988-10-06 1993-04-20 Mitsui Toatsu Chemicals Inc. Heterocyclic compounds and anticancer-drug potentiaters conaining them as effective components
JPH0779706B2 (ja) * 1990-03-22 1995-08-30 田辺製薬株式会社 ２―クロロ―３―ヒドロキシ―３―フエニルプロピオン酸エステル類の製法
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (ru) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
WO1997030035A1 (en) * 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
SK284073B6 (sk) * 1996-04-12 2004-09-08 Warner-Lambert Company Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze
EP0912559B1 (en) * 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
EP0865202A4 (en) 1996-10-02 2002-01-16 Sony Corp TELEVISION RECEIVER, METHOD FOR SETTING UP A RECEIVING CHANNEL AND IMAGE PROCESSING METHOD
US6225318B1 (en) * 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
HUP0100287A3 (en) 1997-11-11 2003-04-28 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
WO1999044612A1 (en) 1998-03-02 1999-09-10 Cocensys, Inc. Substituted quinazolines and analogs and the use thereof
US6017922A (en) * 1998-05-18 2000-01-25 U.S. Bioscience, Inc. Thermally stable trimetrexates and processes for producing the same
WO2000031048A1 (en) 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
US6189091B1 (en) * 1998-12-02 2001-02-13 Ip First, L.L.C. Apparatus and method for speculatively updating global history and restoring same on branch misprediction detection
IL144214A0 (en) 1999-01-13 2002-05-23 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
HK1046688A1 (zh) * 1999-09-21 2003-01-24 Astrazeneca Ab 喹唑啉化合物和含有喹唑啉化合物的藥物組合物
AU3092901A (en) * 2000-02-17 2001-08-27 Bristol Myers Squibb Co Aniline-derived ligands for the thyroid receptor
DE60106022T2 (de) * 2000-06-06 2006-03-09 Pfizer Products Inc., Groton Thiophenverbindungen zur verwendung als antikrebsmittel
WO2001098277A2 (en) * 2000-06-22 2001-12-27 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth
AU7307101A (en) 2000-06-30 2002-01-14 Glaxo Group Ltd Quinazoline ditosylate salt compounds
WO2003015778A1 (en) 2001-08-17 2003-02-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003037252A2 (en) 2001-10-30 2003-05-08 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2005515176A (ja) * 2001-11-03 2005-05-26 アストラゼネカ アクチボラグ 抗腫瘍剤としてのキナゾリン誘導体
US7488823B2 (en) * 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
WO2004064718A2 (en) * 2003-01-23 2004-08-05 T.K. Signal Ltd. Irreversible inhibitors of egf receptor tyrosine kinases and uses thereof
PE20040945A1 (es) * 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
WO2004106308A1 (en) * 2003-05-27 2004-12-09 Pfizer Products Inc. Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
EP1660090B1 (en) 2003-08-14 2012-11-21 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
JP2007502807A (ja) * 2003-08-18 2007-02-15 ファイザー・プロダクツ・インク Ｅｒｂｂ２抗がん剤の投与スケジュール
JP2007510708A (ja) * 2003-11-06 2007-04-26 ファイザー・プロダクツ・インク 癌の治療における選択的ｅｒｂＢ２阻害剤／抗ｅｒｂＢ抗体の組合せ
KR100735639B1 (ko) * 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
PL2090575T3 (pl) 2005-11-15 2011-09-30 Array Biopharma Inc Sposoby i związki pośrednie do otrzymywania pochodnych N4-fenylo-chinazolino-4-aminy

Also Published As

Publication number Publication date
EP2377539A1 (en) 2011-10-19
US9676791B2 (en) 2017-06-13
ZA200601333B (en) 2007-05-30
US20130245256A1 (en) 2013-09-19
US20210269455A1 (en) 2021-09-02
US7585975B2 (en) 2009-09-08
US20090270621A1 (en) 2009-10-29
US20210284656A9 (en) 2021-09-16
CN1852714A (zh) 2006-10-25
US7777032B2 (en) 2010-08-17
US20080194558A1 (en) 2008-08-14
US7501427B2 (en) 2009-03-10
US10221194B2 (en) 2019-03-05
US20050101616A1 (en) 2005-05-12
US11174273B2 (en) 2021-11-16
SI1660090T1 (sl) 2013-02-28
US20190161500A1 (en) 2019-05-30
US20170260202A1 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
TW200519096A (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
MXPA05011296A (es) Conjugados de fosfonato inhibidores de la cinasa.
UA89038C2 (en) Pyrrolotriazine compounds as kinase inhibitors
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
YU84603A (sh) Novi inhibitori tirozin kinaze
WO2005002626A8 (en) Therapeutic phosphonate compounds
TW200614996A (en) Antiviral compounds
UA91688C2 (en) Antiviral compounds
WO2004096286A3 (en) Antiviral phosphonate analogs
WO2004009784A3 (en) Novel inhibitors of kinases
MY137040A (en) Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment
MY141220A (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
TW200420565A (en) C-6 modified indazolylpyrrolotriazines
GB0112348D0 (en) Compounds
EA200300829A1 (ru) Производные 1-арил- или 1-алкилсульфонилбензазола в качестве лигандов 5-гидрокситриптамина-6
AU2003228770A8 (en) Substituted pyrazolopyrimidines
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
WO2004096233A3 (en) Nucleoside phosphonate conjugates
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
UA90659C2 (ru) Аналоги хиназолина как ингибиторы рецепторных тирозинкиназ
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
MXPA05011294A (es) Compuestos de fosfonato anti-inflamatorios.
EP1773791A4 (en) PYRROLOTRIAZINVERBINDUNGEN